EE04800B1 - Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form - Google Patents

Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form

Info

Publication number
EE04800B1
EE04800B1 EEP200000329A EEP200000329A EE04800B1 EE 04800 B1 EE04800 B1 EE 04800B1 EE P200000329 A EEP200000329 A EE P200000329A EE P200000329 A EEP200000329 A EE P200000329A EE 04800 B1 EE04800 B1 EE 04800B1
Authority
EE
Estonia
Prior art keywords
dosage form
oral dosage
preparation
active ingredient
acid unstable
Prior art date
Application number
EEP200000329A
Other languages
Estonian (et)
Inventor
Linder Rudolf
Dietrich Rango
Original Assignee
Byk Gulden Lomberg Chemische Fabrik Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26042262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04800(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997154324 external-priority patent/DE19754324A1/en
Priority claimed from DE1998122549 external-priority patent/DE19822549A1/en
Application filed by Byk Gulden Lomberg Chemische Fabrik Gmbh filed Critical Byk Gulden Lomberg Chemische Fabrik Gmbh
Publication of EE200000329A publication Critical patent/EE200000329A/en
Publication of EE04800B1 publication Critical patent/EE04800B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Novel administration forms for acid-labile active compounds are described. The novel administration forms have no enteric layers and are suitable for oral administration.
EEP200000329A 1997-12-08 1998-12-08 Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form EE04800B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1997154324 DE19754324A1 (en) 1997-12-08 1997-12-08 Easily prepared oral dosage forms for acid-labile drugs, especially proton pump inhibitors
DE1998122549 DE19822549A1 (en) 1998-05-20 1998-05-20 New suppository formulations for acid-labile drugs
PCT/EP1998/008036 WO1999029320A1 (en) 1997-12-08 1998-12-08 Novel administration form comprising an acid-labile active compound

Publications (2)

Publication Number Publication Date
EE200000329A EE200000329A (en) 2001-08-15
EE04800B1 true EE04800B1 (en) 2007-04-16

Family

ID=26042262

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200000331A EE04576B1 (en) 1997-12-08 1998-12-08 Suppository for acid-unstable active substances, method of preparation, unit of action and method of preparation and preparation
EEP200000329A EE04800B1 (en) 1997-12-08 1998-12-08 Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EEP200000331A EE04576B1 (en) 1997-12-08 1998-12-08 Suppository for acid-unstable active substances, method of preparation, unit of action and method of preparation and preparation

Country Status (16)

Country Link
US (5) US6383510B1 (en)
EP (4) EP1037607B1 (en)
JP (2) JP4612184B2 (en)
AT (3) ATE303809T1 (en)
AU (2) AU748209B2 (en)
CA (2) CA2310585C (en)
DE (3) DE69831504T2 (en)
DK (2) DK1037607T3 (en)
EE (2) EE04576B1 (en)
ES (4) ES2362418T3 (en)
HU (2) HUP0100043A2 (en)
IL (3) IL136285A0 (en)
PL (2) PL195266B1 (en)
PT (1) PT1037607E (en)
SI (2) SI1037634T1 (en)
WO (2) WO1999029320A1 (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
ATE303809T1 (en) * 1997-12-08 2005-09-15 Altana Pharma Ag ORAL FORM OF ADMINISTRATION CONTAINING A PROTON PUMP INHIBITOR (E.G. PANTOPRAZOLE)
DE69925007T2 (en) * 1998-09-21 2006-02-02 Amato Pharmaceutical Products, Ltd., Fukuchiyama ORAL DRUG DELIVERY SYSTEM FOR INCREASING THE BIOVERABILITY OF ACTIVATED GLYCYRHICINE
FR2793688B1 (en) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques GASTROPROTEGED MICROGRANULES, PROCESS FOR OBTAINING AND PHARMACEUTICAL PREPARATIONS
JP4980527B2 (en) * 1999-06-07 2012-07-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel formulations and dosage forms containing acid labile active compounds
SE9902386D0 (en) * 1999-06-22 1999-06-22 Astra Ab New formulation
KR100647901B1 (en) * 1999-07-09 2006-11-17 보령제약 주식회사 Sephacller-containing sustained release pharmaceutical composition and preparation method thereof
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
AU2002234545A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
JP4241041B2 (en) * 2000-12-07 2009-03-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Paste-form pharmaceutical product containing an acid-degradable active ingredient
UA80393C2 (en) * 2000-12-07 2007-09-25 Алтана Фарма Аг Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
CN1876647A (en) * 2001-02-02 2006-12-13 特瓦制药工业有限公司 Benzimidazole compound products
SE0100822D0 (en) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
JP4310605B2 (en) 2001-05-25 2009-08-12 大塚製薬株式会社 Pharmaceutical composition
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP1411900B2 (en) * 2001-06-01 2013-12-04 Pozen, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
GB0120123D0 (en) * 2001-08-17 2001-10-10 Upperton Ltd Preparation of microparticles
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2004004690A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
EP1603537A4 (en) * 2003-02-20 2009-11-04 Santarus Inc IMMEDIATE RELEASE OF OMEPRAZOLE ANTACIDAL COMPLEX WITH NEW FORMULATION FOR RAPID AND PROLONGED ELIMINATION OF GASTRIC ACID
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
DK1606261T3 (en) 2003-03-10 2010-01-18 Nycomed Gmbh Hitherto unknown method of making roflumilast
PE20050150A1 (en) 2003-05-08 2005-03-22 Altana Pharma Ag A DOSAGE FORM CONTAINING (S) -PANTOPRAZOLE AS AN ACTIVE INGREDIENT
CL2004000983A1 (en) 2003-05-08 2005-03-04 Altana Pharma Ag ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES DIHYDRATED MAGNETIC PANTOPRAZOL, WHERE THE TABLET FORM IS COMPOSED BY A NUCLEUS, A MIDDLE COAT AND AN OUTER LAYER; AND USE OF PHARMACEUTICAL COMPOSITION IN ULCERAS AND
EP2112920B1 (en) * 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
JP2006528181A (en) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528182A (en) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド Pharmaceutical preparations and treatment of digestive diseases caused by acids
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005032554A1 (en) 2003-10-03 2005-04-14 Astron Research Pvt. Ltd A novel transmucosal delivery system
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
JP2007513145A (en) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク Method for producing pharmaceutical fine particles
JP2007513143A (en) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク Spray coagulation process for producing multiparticulate azithromycin compositions preferably using poloxamer and glycerides using an extruder
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
JP2007513139A (en) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク Multiparticulate compositions with improved stability
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CA2547239A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
JP2007522217A (en) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド Combination of proton pump inhibitor, buffer and non-steroidal anti-inflammatory drug
US20050214370A1 (en) * 2004-03-26 2005-09-29 Sarama Robert J Stable coating agent comprising sterol
US8968768B2 (en) 2004-03-29 2015-03-03 Wyeth Llc Phytosterol nutritional supplements
CA2560595C (en) 2004-03-29 2013-01-22 Wyeth Multi-vitamin and mineral nutritional supplements
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060034934A1 (en) * 2004-08-13 2006-02-16 Deguise Matthew L Agglomeration of sterol particles
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
KR20070109985A (en) 2004-11-22 2007-11-15 아나디스 리미티드 Bioactive Composition
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
AU2006224619B2 (en) * 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007112581A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US9233092B2 (en) 2006-07-25 2016-01-12 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EA201100313A1 (en) 2008-09-09 2011-10-31 Астразенека Аб METHOD OF DELIVERY OF THE PHARMACEUTICAL COMPOSITION TO THE PATIENT NEEDING THIS
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
EP2338477A1 (en) * 2009-12-15 2011-06-29 bene-Arzneimittel GmbH Suppository comprising pantoprazole
EP2611416B1 (en) * 2010-09-03 2015-08-19 Pharmaterials Ltd. Pharmaceutical composition suitable for use in a dry powder inhaler
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2012171540A1 (en) * 2011-06-15 2012-12-20 Bene-Arzneimittel Gmbh Suppository comprising pantoprazole comprised in pellets with a cellulose core
BR112014016085A8 (en) 2011-12-28 2017-07-04 Pozen Inc Enhanced compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
CN117338729B (en) * 2023-12-06 2024-02-13 山东国邦药业有限公司 Erythromycin thiocyanate soluble particles and preparation method thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931147A (en) * 1959-10-23 1963-07-10 Olin Mathieson Sustained release pharmaceutical preparations and methods for their manufacture
SE7804231L (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
NL193682C (en) * 1987-05-14 2000-07-04 Glaxo Group Ltd Coated Cefuroxime Maxetil Composition.
JP2694361B2 (en) * 1989-02-09 1997-12-24 アストラ アクチエボラグ Antibacterial agent
KR930000861B1 (en) * 1990-02-27 1993-02-08 한미약품공업 주식회사 Omeprazole rectal composition
DE4035455A1 (en) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab ENANTIOMER SEPARATION
SE502569C2 (en) * 1991-05-31 1995-11-13 British Tech Group Use of an immunologically inert matrix of a sterol and saponins which can form spherical nanoparticles of narrow size distribution such as drug carriers, particles, composition and kits
YU48263B (en) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. PROCEDURE FOR OBTAINING PANTOPRAZOLE PHARMACEUTICAL PRODUCT
JPH05194225A (en) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd Stabilized anti-ulcer drug-containing preparation
JPH05194224A (en) * 1992-09-17 1993-08-03 Yoshitomi Pharmaceut Ind Ltd Stabilized antiulcer agent-containing preparation
SE9301830D0 (en) * 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
ES2145102T3 (en) * 1993-09-09 2000-07-01 Takeda Chemical Industries Ltd FORMULATION COMPRISING AN ANTIBACTERIAL SUBSTANCE AND AN ANTI-ULCER SUBSTANCE.
JPH07145053A (en) * 1993-11-25 1995-06-06 Yoshitomi Pharmaceut Ind Ltd Suppository
SE9402431D0 (en) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
CZ289804B6 (en) * 1994-07-08 2002-04-17 Astrazeneca Ab Multiple units tableted dosage form
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
FR2725623A1 (en) * 1994-10-18 1996-04-19 Flamel Tech Sa MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION
SE9500422D0 (en) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
DE19539361A1 (en) * 1995-10-23 1997-04-24 Basf Ag Process for the preparation of multilayer, solid pharmaceutical forms for oral or rectal administration
FR2740686B1 (en) 1995-11-03 1998-01-16 Sanofi Sa STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION
SE512835C2 (en) * 1996-01-08 2000-05-22 Astrazeneca Ab Dosage form containing a plurality of units all containing acid labile H + K + ATPase inhibitors
SE9600071D0 (en) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (en) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
ATE303809T1 (en) * 1997-12-08 2005-09-15 Altana Pharma Ag ORAL FORM OF ADMINISTRATION CONTAINING A PROTON PUMP INHIBITOR (E.G. PANTOPRAZOLE)
SE9704869D0 (en) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
DE19848849A1 (en) 1998-10-22 2000-04-27 Knoll Ag Free-flowing, homogeneous spheres of active agent, e.g. drug, in auxiliary matrix, obtained by dropping molten mixture from nozzle into fluid for freezing and solidification

Also Published As

Publication number Publication date
DE69831504T2 (en) 2006-06-14
CA2310585A1 (en) 1999-06-17
EP1037607B1 (en) 2004-02-25
WO1999029299A1 (en) 1999-06-17
US20040022854A1 (en) 2004-02-05
ES2216351T3 (en) 2004-10-16
IL136249A (en) 2007-07-04
AU2413099A (en) 1999-06-28
ATE500815T1 (en) 2011-03-15
EP1371361A1 (en) 2003-12-17
SI1037634T1 (en) 2006-02-28
PL341055A1 (en) 2001-03-26
HUP0100043A2 (en) 2001-08-28
AU748209B2 (en) 2002-05-30
CA2310585C (en) 2005-08-23
DE69831504D1 (en) 2005-10-13
DE69821976T2 (en) 2004-12-16
JP4546643B2 (en) 2010-09-15
WO1999029320A1 (en) 1999-06-17
EP1525882A1 (en) 2005-04-27
DK1037634T3 (en) 2005-12-19
DE69842173D1 (en) 2011-04-21
HUP0100065A2 (en) 2001-08-28
AU2160099A (en) 1999-06-28
US6383510B1 (en) 2002-05-07
ATE260090T1 (en) 2004-03-15
US20020090397A1 (en) 2002-07-11
CA2312493A1 (en) 1999-06-17
EE200000329A (en) 2001-08-15
US6569453B2 (en) 2003-05-27
US6884437B2 (en) 2005-04-26
PL341054A1 (en) 2001-03-26
ATE303809T1 (en) 2005-09-15
PT1037607E (en) 2004-07-30
EP1371361B1 (en) 2011-03-09
DK1037607T3 (en) 2004-06-21
SI1037607T1 (en) 2004-08-31
PL195266B1 (en) 2007-08-31
EP1037634B1 (en) 2005-09-07
ES2362418T3 (en) 2011-07-05
ES2249849T3 (en) 2006-04-01
DE69821976D1 (en) 2004-04-01
US6328993B1 (en) 2001-12-11
JP2001525355A (en) 2001-12-11
ES2392684T3 (en) 2012-12-12
EP1037607A1 (en) 2000-09-27
CA2312493C (en) 2007-03-06
JP2001525366A (en) 2001-12-11
PL196163B1 (en) 2007-12-31
EP1037634A1 (en) 2000-09-27
EE200000331A (en) 2001-08-15
EE04576B1 (en) 2006-02-15
JP4612184B2 (en) 2011-01-12
US6607742B2 (en) 2003-08-19
US20020025342A1 (en) 2002-02-28
IL136249A0 (en) 2001-05-20
IL136285A0 (en) 2001-05-20
EP1525882B1 (en) 2012-08-08
AU751066B2 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
EE200000329A (en) Oral Form For Acid-Unstable Active Ingredients, Method Of Preparation And Use Of A Unit Of Acid-Unstable Active Ingredient
AR240250A1 (en) PROCEDURE FOR THE PREPARATION OF A NEW ORAL PHARMACEUTICAL FORMULATION CONTAINING OMEPRAZOLE AS AN ACTIVE INGREDIENT.
SE8804629D0 (en) NEW THERAPEUTICALLY ACTIVE COMPOUNDS
BG106095A (en) NEW MEDICINAL COMPOSITIONS BASED ON ANTICHLINERGY ACTIVE COMPOUNDS AND BETA-MIMETITIS
EE9700328A (en) Solid oral preparation containing olanzapine as active ingredient, method of preparation and use thereof
ATE255410T1 (en) MEDICINAL PRODUCT CONTAINING CLODRONATE AS THE ACTIVE INGREDIENT AND MICROCRYSTALLINE CELLULOSE TREATED WITH SILICON DIOXIDE AS A FILLER
FI963916L (en) Novel stabilized galenic formulations containing an acid-labile benzimidazole compound and their preparation
IT1201087B (en) PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
TR199802698T2 (en) Solid oral dose forms of valsartan.
IT8722790A0 (en) PHARMACOLOGICALLY ACTIVE COMPOUNDS, PROCEDURES FOR THEIR PREPARATION AND COMPOSITIONS THAT CONTAIN THEM.
ITFI930247A1 (en) ANTAGONISTS OF TACHYCININS, PROCEDURE FOR THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL FORMULATIONS.
ATE260646T1 (en) RAPID DISSOLVING ORAL DOSAGE FORM
NO20011721D0 (en) N-aralkylaminotetralins as ligands for neuropeptide Y Y5 receptor
UY26372A1 (en) "IMIDAZO-3-IL-AMINAS BICÍCLICAS PROCEDURE FOR ITS PREPARATION AND DRUGS THAT CONTAIN THEM"
KR890700125A (en) New benzimidazole derivatives, preparation method thereof and pharmaceutical composition containing the compound
ATE260650T1 (en) ORAL DOSAGE FORMS FOR ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
SE9700885D0 (en) New pharmaceutical formulation
DE59907481D1 (en) CONTROLLING RELEASING PHARMACEUTICAL COMPOSITION WITH TILIDINE MESYLATE AS AN ACTIVE SUBSTANCE
NO883750L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PIPERIDE INGREDIENTS.
SE8804628D0 (en) NEW COMPOUNDS
NO910874D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PIPERIDE INGREDIENTS.
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
IT1256623B (en) TACHYCHININ ANTAGONISTS, PROCEDURE FOR THEIR PREPARATION AND USE IN PHARMACEUTICAL FORMULATIONS
NO975680L (en) Oral pharmaceutical preparation of piperidinoalkanol compounds in solution form
FI880210L (en) The method produces an oral stabilized, slow and controlled release pharmaceutical preparation of the active ingredient

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20091208